drugset
drugset / Trial / NCT05632848

Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients

NCT05632848 ↗

Phase 2 Completed 47 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of a new treatment regimen (Chidamide combined with Zimberelimab) in the treatment of patients with metastatic triple negative breast cancer after the second-line therapy.

Timeline

Start
2022-06-15
Primary completion
2024-10-23
Completion
2025-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Tucidinostat Small molecule 30 mg Oral
Subject Zimberelimab Monoclonal antibody 240 mg Intravenous

Indications

triple-negative breast carcinoma